United States: Biocon Settles With Janssen, Securing U.S. Market Entry Date For Ustekinumab Biosimilar - Goodwin Procter LLP

Mondaq

15 Mar 2024 0 shares 1 views

United States: Biocon Settles With Janssen, Securing U.S. Market Entry Date For Ustekinumab Biosimilar - Goodwin Procter LLP

Mondaq

Published 15 Mar 2024

On February 29, Biocon Biologics Ltd announced that it signed a settlement and license agreement with Janssen Biotech Inc. and Johnson & Johnson ("J&J") regarding Bmab 1200, Biocon's proposed biosimilar to STELARA.

Full Article

United States: Biocon Settles With Bayer And Regeneron, Securing Canada Market Entry Date For Aflibercept Biosimilar - Goodwin Procter LLP

On March 4, Biocon Biologics Ltd. announced it has signed a settlement agreement with Bayer Inc. and Regeneron Pharmaceuticals,..

Mondaq 15 Mar 2024

United States: Biocon Settles With Janssen, Securing U.S. Market Entry Date For Ustekinumab Biosimilar - Goodwin Procter LLP

United States: Biocon Settles With Janssen, Securing U.S. Market Entry Date For Ustekinumab Biosimilar - Goodwin Procter LLP

You might like

Related news coverage

United States: Biocon Settles With Bayer And Regeneron, Securing Canada Market Entry Date For Aflibercept Biosimilar - Goodwin Procter LLP

Advertisement